Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphokine-activated killer cell suppressor factor in malignant effusions.

J J Pelton1, D D Taylor, W C Fowler

  • 1Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pa 19111.

Archives of Surgery (Chicago, Ill. : 1960)
|April 1, 1991
PubMed
Summary

Tumor-released products can suppress immune responses. This study identified a tumor-derived suppressor factor that inhibits lymphokine-activated killer (LAK) cell activity and proliferation, potentially impacting cancer immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial.

Annals of surgical oncology·2026
Same author

First Report of Bloat Nematode (Ditylenchus dipsaci) Infecting Garlic in Ohio.

Plant disease·2019
Same author

A Dividing Stretcher.

The Indian medical gazette·2017
Same author

Cellulitis of the Orbit.

The Indian medical gazette·2017
Same author

Root-Knot Nematode Parasitism Suppresses Host RNA Silencing.

Molecular plant-microbe interactions : MPMI·2017
Same author

Knowledge, attitudes and practices towards blood donation in Barbados.

Transfusion medicine (Oxford, England)·2016

Area of Science:

  • Immunology
  • Cancer Biology
  • Biochemistry

Background:

  • Tumor-derived products can influence the immune system.
  • Understanding these interactions is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate whether tumor-released products inhibit lymphokine-activated killer (LAK) cell activation.
  • To characterize the nature of the suppressive factor(s).

Main Methods:

  • Human peripheral blood lymphocytes were cultured with recombinant interleukin 2 to activate LAK cells.
  • Malignant effusions and conditioned media were added during LAK cell activation.
  • Cytotoxicity was measured using a sodium chromate release assay.
  • Proliferation was assessed, and suppressive factors were fractionated using chromatography.

Related Experiment Videos

Main Results:

  • Eight out of ten malignant effusions/media suppressed LAK cell cytotoxicity.
  • Seven out of ten samples inhibited LAK cell proliferation.
  • Suppression was dose- and time-dependent.
  • Seven suppressive fractions (1 x 10(5) to 3 x 10(5) d) were isolated, suggesting a large, multimeric structure.

Conclusions:

  • Tumor-released products can significantly inhibit LAK cell function.
  • A large, potentially multimeric suppressor factor is involved.
  • Further characterization of this factor could inform novel cancer treatment strategies.